Dr. Maeng is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10 Center Dr Room 3B37
MSC 1578
Bethesda, MD 20892Phone+1 240-781-3253Fax+1 301-480-4983
Summary
- Dr. Hoyoung Maeng is an oncology specialist based in Bethesda, MD, with significant experience in immunotherapy, vaccine-based tumor therapy, clinical research, and tumor immunology. She completed her medical degree at Yonsei University College of Medicine and pursued advanced fellowships in leukemia and post-doctoral research at the University of Texas M.D. Anderson Cancer Center. Currently, she is a member of the Center for Immuno-Oncology at the NCI. Her research interests include cancer vaccines, overcoming immune checkpoint inhibitor resistance, and hereditary cancer syndromes such as Lynch syndrome. Dr. Maeng has led several clinical trials including the studies using NCI-developed dendritic cell vaccine platforms and immunotherapy for cancer. She has been recognized with numerous awards, including AACR/MedImmune Fellowship on reversing resistance to apoptosis in cancer.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2015 - 2017
University of Texas M.D. Anderson Cancer CenterFellowship, Leukemia, 2014 - 2015
MetroWest Medical CenterResidency, Internal Medicine, 2011 - 2014
Severance Hospital, Yonsei UniversityHematology, Malignant Hematology, Hematopoietic Stem Cell Transplant Service, 2003 - 2004- Severance Hospital, Yonsei UniversityInternal Medicine/Hematology-Oncology, 1999 - 2003
- Severance Hospital/Yonsei UniversityInternship, 1998 - 1999
Yonsei University College of MedicineClass of 1998- University of Texas M.D. Anderson Cancer CenterPost-Doctoral Fellowship, Research Fellowship
Certifications & Licensure
MD State Medical License 2016 - 2025
DC State Medical License 2015 - 2016
MA State Medical License 2015 - 2016
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Dr. Moon scholarship Yonsei Univ College of Medicine alimni Association. 2012
- AACR-MedImmune fellowship AACR, 2007
- ASH Travel Award ASH, 2007
Clinical Trials
- A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults Start of enrollment: 2009 Jun 29
- A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer Start of enrollment: 2009 May 11
- Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing Start of enrollment: 2013 Mar 04
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsSecond-generation checkpoint inhibitors and Treg depletion synergize with a mouse cancer vaccine in accordance with tumor microenvironment characterization.William Becker, Purevdorj B Olkhanud, Noriko Seishima, Paloma A Moreno, Katherine C Goldfarbmuren
Journal for Immunotherapy of Cancer. 2024-07-01 - 6 citationsRevealing the Heterogeneity of the Tumor Ecosystem of Cholangiocarcinoma through Single-Cell Transcriptomics.Jihye L Golino, Xin Wang, Hoyoung M Maeng, Changqing Xie
Cells. 2023-03-10 - 14 citationsMPAsoftware enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays.Joshua A Welsh, Bryce Killingsworth, Julia Kepley, Tim Traynor, Sean Cook
Cell Reports Methods. 2022-01-24
Press Mentions
New Vaccine Could Delay ADT Use in Stage D0 Prostate CancerDecember 30th, 2019
Professional Memberships
- Member
- Member
- Society for Immunotherapy of CancerMember
Other Languages
- Korean
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
